alanine and HIV
alanine has been researched along with HIV in 19 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women." | 8.12 | Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022) |
| "A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhibitor-based single-tablet regimen." | 4.98 | Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. ( Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N, 2018) |
| "Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women." | 4.12 | Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022) |
| " Efficacy against vaginal simian-HIV (SHIV) infection was investigated in six pigtailed macaques that received two tenofovir alafenamide implants (0." | 4.12 | Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. ( Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022) |
| " We used a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigate whether TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection." | 3.91 | Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques. ( Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S, 2019) |
| " Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations." | 1.48 | A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. ( Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018) |
Research
Studies (19)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Roa, PE | 1 |
| Bazzi, R | 1 |
| Bukkems, VE | 1 |
| Necsoi, C | 1 |
| Hidalgo Tenorio, C | 1 |
| Garcia, C | 1 |
| Alba Alejandre, I | 1 |
| Weiss, F | 1 |
| Lambert, JS | 1 |
| van Hulzen, A | 1 |
| Richel, O | 1 |
| Te Brake, LHM | 1 |
| van der Meulen, E | 1 |
| Burger, D | 1 |
| Konopnicki, D | 1 |
| Colbers, A | 1 |
| De Clercq, E | 2 |
| Ma, J | 1 |
| Nance, RM | 1 |
| Delaney, JAC | 1 |
| Whitney, BM | 1 |
| Bamford, L | 1 |
| Gravett, RM | 1 |
| Moore, RD | 1 |
| Napravnik, S | 1 |
| Mayer, KH | 1 |
| Jacobson, JM | 1 |
| Christopoulos, K | 1 |
| Burkholder, GA | 1 |
| Keruly, J | 1 |
| Eron, JJ | 1 |
| Martin, J | 1 |
| Cachay, ER | 1 |
| Saag, MS | 1 |
| Crane, HM | 1 |
| Kitahata, MM | 1 |
| Massud, I | 2 |
| Krovi, A | 1 |
| Nishiura, K | 2 |
| Ruone, S | 2 |
| Li, L | 1 |
| Holder, A | 2 |
| Gary, J | 1 |
| Mills, P | 1 |
| Mitchell, J | 1 |
| Khalil, G | 2 |
| Pan, Y | 2 |
| Luecke, E | 1 |
| Gatto, G | 1 |
| Heneine, W | 2 |
| García-Lerma, JG | 2 |
| Johnson, L | 1 |
| van der Straten, A | 1 |
| Dobard, C | 1 |
| Liu, W | 1 |
| Yu, S | 1 |
| Yan, B | 1 |
| Ma, R | 1 |
| Zhang, Q | 1 |
| Zhang, YS | 1 |
| Xu, B | 1 |
| Tong, ZW | 1 |
| Zhao, CS | 1 |
| Zhao, RG | 1 |
| Garrett, KL | 1 |
| Chen, J | 1 |
| Maas, BM | 1 |
| Cottrell, ML | 1 |
| Prince, HA | 1 |
| Sykes, C | 1 |
| Schauer, AP | 1 |
| White, N | 1 |
| Dumond, JB | 1 |
| Squillace, N | 1 |
| Bozzi, G | 1 |
| Colella, E | 1 |
| Gori, A | 1 |
| Bandera, A | 1 |
| Cong, ME | 1 |
| Dinh, C | 1 |
| Lipscomb, J | 1 |
| Johnson, R | 1 |
| Deyounks, F | 1 |
| Rooney, JF | 1 |
| Babusis, D | 1 |
| Park, Y | 1 |
| McCallister, S | 1 |
| Callebaut, C | 1 |
| Okamoto, Y | 1 |
| Bernstein, JD | 1 |
| Shikano, S | 1 |
| Stanley, BJ | 1 |
| Ehrlich, ES | 1 |
| Short, L | 1 |
| Yu, Y | 1 |
| Xiao, Z | 1 |
| Yu, XF | 1 |
| Xiong, Y | 1 |
| del Alamo, M | 1 |
| Neira, JL | 1 |
| Mateu, MG | 1 |
| Haugaard, SB | 1 |
| Andersen, O | 1 |
| Dela, F | 1 |
| Holst, JJ | 1 |
| Storgaard, H | 1 |
| Fenger, M | 1 |
| Iversen, J | 1 |
| Madsbad, S | 1 |
| Ma, X | 1 |
| Zheng, W | 1 |
| Wei, D | 1 |
| Ma, Y | 1 |
| Wang, T | 1 |
| Wang, J | 1 |
| Liu, Q | 1 |
| Yang, S | 1 |
| Fossey, C | 1 |
| Huynh, NT | 1 |
| Vu, AH | 1 |
| Vidu, A | 1 |
| Zarafu, I | 1 |
| Laduree, D | 1 |
| Schmidt, S | 1 |
| Laumond, G | 1 |
| Aubertin, AM | 1 |
| Balzarini, J | 1 |
| Kruining, J | 1 |
| Wedgwood, O | 1 |
| Pannecouque, C | 1 |
| Aquaro, S | 1 |
| Perno, CF | 1 |
| Naesens, L | 1 |
| Witvrouw, M | 1 |
| Heijtink, R | 1 |
| McGuigan, C | 1 |
| Ashkenazi, A | 1 |
| Presta, LG | 1 |
| Marsters, SA | 1 |
| Camerato, TR | 1 |
| Rosenthal, KA | 1 |
| Fendly, BM | 1 |
| Capon, DJ | 1 |
| Ahluwalia, G | 1 |
| Cooney, DA | 1 |
| Mitsuya, H | 1 |
| Fridland, A | 1 |
| Flora, KP | 1 |
| Hao, Z | 1 |
| Dalal, M | 1 |
| Broder, S | 1 |
| Johns, DG | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)[NCT00119769] | Phase 4 | 46 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
2 reviews available for alanine and HIV
| Article | Year |
|---|---|
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Dr | 2021 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV | 2018 |
Other Studies
17 other studies available for alanine and HIV
| Article | Year |
|---|---|
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; | 2022 |
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; T | 2022 |
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; | 2022 |
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Li | 2022 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections | 2020 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle | 2018 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmi | 2019 |
Role of C-terminal membrane-proximal basic residues in cell surface trafficking of HIV coreceptor GPR15 protein.
Topics: Alanine; Amino Acid Sequence; Cell Membrane; Endoplasmic Reticulum; Flow Cytometry; Golgi Apparatus; | 2013 |
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Cell Line; Consensus Sequence; Conserved Sequ | 2008 |
Thermodynamic dissection of a low affinity protein-protein interface involved in human immunodeficiency virus assembly.
Topics: Alanine; Capsid Proteins; Chromatography, Gel; Circular Dichroism; Dimerization; Dose-Response Relat | 2003 |
Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.
Topics: Adult; Alanine; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Cholesterol, | 2005 |
Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.
Topics: Alanine; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Cell Line, Tumor; Escherichia coli | 2006 |
Synthesis and anti-HIV evaluation of hybrid-type prodrugs conjugating HIV integrase inhibitors with d4t by self-cleavable spacers containing an amino acid residue.
Topics: Alanine; Anti-HIV Agents; Cells, Cultured; Dimerization; HIV; HIV Integrase Inhibitors; Inhibitory C | 2007 |
Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Cells, Cult | 1997 |
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.
Topics: Alanine; Amino Acid Sequence; Antibodies, Monoclonal; Binding Sites; CD4 Antigens; Cell Line; Comput | 1990 |
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.
Topics: Alanine; Animals; Cell Line; Chromatography, High Pressure Liquid; Deoxyadenine Nucleotides; Deoxyri | 1987 |